Ey. Moon et al., Effect of DW2282 on the induction of methemoglobinemia, hypoglycemia or WBC count and hematological changes, ARCH PH RES, 22(6), 1999, pp. 565-570
DW2282,(S)-(+)-4-phenyl-1-[1-(4-aminobenzoyl)-indoline-5-sulfonyl]-4,5-dihy
dro-2-imidazolone hydrochloride, is a new anticancer agent which is thought
to exhibit a characteristic mechanism of action in the inhibition of tumor
growth. In this study, we estimated the toxicities of DW2282 in mice. When
mice were orally dosed for five consecutive days at the dosages of 50, 100
and 150 mg/kg, DW2282 did not induce methemoglobinemia and hypoglycemia at
any of these doses. However, increased ALT and AST values were observed in
the 150 mg/kg dosing group, and white blood cells (WBC) were significantly
decreased at all doses. However, the changes in WBC count, ALT and AST imm
ediately reversed after the cessation of drug administration. In addition,
we found that DW2282 did not cause an increase in hemolysis in human blood.
Taken together, these data suggested that DW2282 may have a relatively low
lever of toxicity, and that there may be a quick recovery from any toxicit
y it does produce.